Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia

An open-label, extension study

Shinya Katsutani, Yoshiaki Tomiyama, Akiro Kimura, Yoshitaka Miyakawa, Shinichiro Okamoto, Yasushi Okoshi, Haruhiko Ninomiya, Hiroshi Kosugi, Kazuyoshi Ishii, Yasuo Ikeda, Toshihiro Hattori, Koichi Katsura, Yuzuru Kanakura

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Eltrombopag is an oral, nonpeptide, thrombopoietin receptor agonist approved for treatment of chronic immune thrombocytopenia (ITP). The safety, tolerability, and efficacy of eltrombopag for up to 3 years were evaluated in 19 Japanese patients with chronic ITP who had completed a prior 6-month study. Patients received eltrombopag once daily at the last dosage received in the prior study (12.5, 25, or 50 mg). Dose adjustments and treatment interruptions were permitted to maintain platelet counts of 50,000-200,000/μL. Primary evaluations were safety and tolerability of long-term eltrombopag treatment. The median duration of exposure was 27.5 months (range, 9.9-32.3). Adverse events were similar to those reported with short-term use of eltrombopag, and none led to treatment discontinuation. Nine serious adverse events were reported. Median platelet counts began to increase after 1 week of treatment and remained above 50,000/μL for most assessments. Bleeding episodes decreased from 63 % at baseline to 21 % after 2 weeks of treatment and remained below baseline for all assessments. Of 15 patients receiving concomitant baseline ITP medications, 10 permanently discontinued or achieved a sustained reduction of at least one treatment without requiring rescue treatment. Long-term treatment with eltrombopag was safe, well tolerated, and effective in Japanese patients with chronic ITP.

Original languageEnglish
Pages (from-to)323-330
Number of pages8
JournalInternational Journal of Hematology
Volume98
Issue number3
DOIs
Publication statusPublished - 2013 Sep

Fingerprint

Idiopathic Thrombocytopenic Purpura
Therapeutics
Platelet Count
Thrombopoietin Receptors
Safety
eltrombopag
Hemorrhage

Keywords

  • Bleeding
  • Platelets
  • Thrombopoietin receptor agonist

ASJC Scopus subject areas

  • Hematology

Cite this

Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia : An open-label, extension study. / Katsutani, Shinya; Tomiyama, Yoshiaki; Kimura, Akiro; Miyakawa, Yoshitaka; Okamoto, Shinichiro; Okoshi, Yasushi; Ninomiya, Haruhiko; Kosugi, Hiroshi; Ishii, Kazuyoshi; Ikeda, Yasuo; Hattori, Toshihiro; Katsura, Koichi; Kanakura, Yuzuru.

In: International Journal of Hematology, Vol. 98, No. 3, 09.2013, p. 323-330.

Research output: Contribution to journalArticle

Katsutani, S, Tomiyama, Y, Kimura, A, Miyakawa, Y, Okamoto, S, Okoshi, Y, Ninomiya, H, Kosugi, H, Ishii, K, Ikeda, Y, Hattori, T, Katsura, K & Kanakura, Y 2013, 'Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: An open-label, extension study', International Journal of Hematology, vol. 98, no. 3, pp. 323-330. https://doi.org/10.1007/s12185-013-1401-1
Katsutani, Shinya ; Tomiyama, Yoshiaki ; Kimura, Akiro ; Miyakawa, Yoshitaka ; Okamoto, Shinichiro ; Okoshi, Yasushi ; Ninomiya, Haruhiko ; Kosugi, Hiroshi ; Ishii, Kazuyoshi ; Ikeda, Yasuo ; Hattori, Toshihiro ; Katsura, Koichi ; Kanakura, Yuzuru. / Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia : An open-label, extension study. In: International Journal of Hematology. 2013 ; Vol. 98, No. 3. pp. 323-330.
@article{f7a8a50be0234d02b05476f73e8347be,
title = "Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: An open-label, extension study",
abstract = "Eltrombopag is an oral, nonpeptide, thrombopoietin receptor agonist approved for treatment of chronic immune thrombocytopenia (ITP). The safety, tolerability, and efficacy of eltrombopag for up to 3 years were evaluated in 19 Japanese patients with chronic ITP who had completed a prior 6-month study. Patients received eltrombopag once daily at the last dosage received in the prior study (12.5, 25, or 50 mg). Dose adjustments and treatment interruptions were permitted to maintain platelet counts of 50,000-200,000/μL. Primary evaluations were safety and tolerability of long-term eltrombopag treatment. The median duration of exposure was 27.5 months (range, 9.9-32.3). Adverse events were similar to those reported with short-term use of eltrombopag, and none led to treatment discontinuation. Nine serious adverse events were reported. Median platelet counts began to increase after 1 week of treatment and remained above 50,000/μL for most assessments. Bleeding episodes decreased from 63 {\%} at baseline to 21 {\%} after 2 weeks of treatment and remained below baseline for all assessments. Of 15 patients receiving concomitant baseline ITP medications, 10 permanently discontinued or achieved a sustained reduction of at least one treatment without requiring rescue treatment. Long-term treatment with eltrombopag was safe, well tolerated, and effective in Japanese patients with chronic ITP.",
keywords = "Bleeding, Platelets, Thrombopoietin receptor agonist",
author = "Shinya Katsutani and Yoshiaki Tomiyama and Akiro Kimura and Yoshitaka Miyakawa and Shinichiro Okamoto and Yasushi Okoshi and Haruhiko Ninomiya and Hiroshi Kosugi and Kazuyoshi Ishii and Yasuo Ikeda and Toshihiro Hattori and Koichi Katsura and Yuzuru Kanakura",
year = "2013",
month = "9",
doi = "10.1007/s12185-013-1401-1",
language = "English",
volume = "98",
pages = "323--330",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia

T2 - An open-label, extension study

AU - Katsutani, Shinya

AU - Tomiyama, Yoshiaki

AU - Kimura, Akiro

AU - Miyakawa, Yoshitaka

AU - Okamoto, Shinichiro

AU - Okoshi, Yasushi

AU - Ninomiya, Haruhiko

AU - Kosugi, Hiroshi

AU - Ishii, Kazuyoshi

AU - Ikeda, Yasuo

AU - Hattori, Toshihiro

AU - Katsura, Koichi

AU - Kanakura, Yuzuru

PY - 2013/9

Y1 - 2013/9

N2 - Eltrombopag is an oral, nonpeptide, thrombopoietin receptor agonist approved for treatment of chronic immune thrombocytopenia (ITP). The safety, tolerability, and efficacy of eltrombopag for up to 3 years were evaluated in 19 Japanese patients with chronic ITP who had completed a prior 6-month study. Patients received eltrombopag once daily at the last dosage received in the prior study (12.5, 25, or 50 mg). Dose adjustments and treatment interruptions were permitted to maintain platelet counts of 50,000-200,000/μL. Primary evaluations were safety and tolerability of long-term eltrombopag treatment. The median duration of exposure was 27.5 months (range, 9.9-32.3). Adverse events were similar to those reported with short-term use of eltrombopag, and none led to treatment discontinuation. Nine serious adverse events were reported. Median platelet counts began to increase after 1 week of treatment and remained above 50,000/μL for most assessments. Bleeding episodes decreased from 63 % at baseline to 21 % after 2 weeks of treatment and remained below baseline for all assessments. Of 15 patients receiving concomitant baseline ITP medications, 10 permanently discontinued or achieved a sustained reduction of at least one treatment without requiring rescue treatment. Long-term treatment with eltrombopag was safe, well tolerated, and effective in Japanese patients with chronic ITP.

AB - Eltrombopag is an oral, nonpeptide, thrombopoietin receptor agonist approved for treatment of chronic immune thrombocytopenia (ITP). The safety, tolerability, and efficacy of eltrombopag for up to 3 years were evaluated in 19 Japanese patients with chronic ITP who had completed a prior 6-month study. Patients received eltrombopag once daily at the last dosage received in the prior study (12.5, 25, or 50 mg). Dose adjustments and treatment interruptions were permitted to maintain platelet counts of 50,000-200,000/μL. Primary evaluations were safety and tolerability of long-term eltrombopag treatment. The median duration of exposure was 27.5 months (range, 9.9-32.3). Adverse events were similar to those reported with short-term use of eltrombopag, and none led to treatment discontinuation. Nine serious adverse events were reported. Median platelet counts began to increase after 1 week of treatment and remained above 50,000/μL for most assessments. Bleeding episodes decreased from 63 % at baseline to 21 % after 2 weeks of treatment and remained below baseline for all assessments. Of 15 patients receiving concomitant baseline ITP medications, 10 permanently discontinued or achieved a sustained reduction of at least one treatment without requiring rescue treatment. Long-term treatment with eltrombopag was safe, well tolerated, and effective in Japanese patients with chronic ITP.

KW - Bleeding

KW - Platelets

KW - Thrombopoietin receptor agonist

UR - http://www.scopus.com/inward/record.url?scp=84884669269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884669269&partnerID=8YFLogxK

U2 - 10.1007/s12185-013-1401-1

DO - 10.1007/s12185-013-1401-1

M3 - Article

VL - 98

SP - 323

EP - 330

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -